03rd week of 2013 patent applcation highlights part 38 |
Patent application number | Title | Published |
20130018013 | BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS - The present disclosure relates to the use and methods of manufacture of bicyclic nucleosides and nucleotides for the treatment and prevention of infectious and proliferative diseases, including microbial infections and cancer. | 2013-01-17 |
20130018014 | New class of therapeutics that enhance small molecule diffusion - The subject application relates to novel compositions containing a diffusion enhancing compound and their use in treating a variety of disorders. | 2013-01-17 |
20130018015 | Nutritional Composition and Methods of Making and Using Same - A Nutritional Composition comprising soluble extractable material from a lignocellulosic source. A method of producing a composition, comprising providing a lignocellulosic source, extracting soluble materials from the lignocellulosic source to produce soluble extractable material, and processing the soluble extractable material to yield a Nutritional Composition, wherein the Nutritional Composition comprises hemicellulose and exhibits pathogen blocking, anti-adhesion activity. | 2013-01-17 |
20130018016 | Agent for Combating Ectoparasites - Disclosed is a composition for killing ectoparasites and/or their eggs, comprising at least one volatile, at room temperature liquid, non-polar organic solvent, 1 to 10 wt.-%, based on the total composition, of at least one spreading agent; and 35 to 65 wt.-%, based on the total composition, of at least one polysiloxane having a viscosity of greater than 90 cSt. | 2013-01-17 |
20130018017 | QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS - The present invention provides compounds of formula (I), their use as PARP inhibitors as well as pharmaceutical compositions comprising said compounds of formula (I) | 2013-01-17 |
20130018018 | NOVEL NUCLEOSIDE PHOSPHONATES AND ANALOGS - Compounds and compositions are provided for treatment, prevention, or amelioration of a variety of medical disorders associated with viral infections and/or cell proliferation. The compounds provided herein are nucleoside phosphonates and esters thereof. | 2013-01-17 |
20130018019 | AROMATIC COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHONATE (S1P) RECEPTOR ACTIVITY - Novel aromatic compounds which are useful as sphingosine-1-phosphate modulators and useful for treating a wide variety of disorders associated with modulation of sphingosine-1-phosphate receptors. | 2013-01-17 |
20130018020 | INHIBITOR FOR MELANIN, AND COSMETIC COMPOSITION CONTAINING SAMEAANM Shin; Hong JuAACI Seongnam-siAACO KRAAGP Shin; Hong Ju Seongnam-si KRAANM Kim; Do HoonAACI SeoulAACO KRAAGP Kim; Do Hoon Seoul KRAANM Kim; Jeong HwanAACI Paju-siAACO KRAAGP Kim; Jeong Hwan Paju-si KRAANM Koh; Hyun JuAACI Anyang-siAACO KRAAGP Koh; Hyun Ju Anyang-si KRAANM Park; Won SeokAACI SeoulAACO KRAAGP Park; Won Seok Seoul KR - The present invention relates to a melanin production inhibitor containing, as active ingredients, tranexamic acid and nicotinic acid amide, which inhibits the formation of skin melanocytes, and to a cosmetic composition which contains the melanin production inhibitor as an active ingredient and has the effects of reducing liver spots, blemishes, freckles and post-inflammatory hyperpigmentation, improving skin tone and texture and whitening the skin. | 2013-01-17 |
20130018021 | 2Alpha-Methyl and 2Beta-Methyl Analogs of 19,26,27-Trinor-(20S)-1Alpha-Hydroxyvitamin D3 and Their Uses - This invention discloses 2α-methyl and 2β-methyl analogs of 19,26,27-trinor-(20S)-1α-hydroxyvitamin D | 2013-01-17 |
20130018022 | PHARMACEUTICAL COMPOSITION INCLUDING A TESTIS EXTRACT AS AN ACTIVE INGREDIENT FOR TREATING AND PREVENTING ANEMIAAANM Choi; In-HoAACI Gyeongsan-siAACO KRAAGP Choi; In-Ho Gyeongsan-si KRAANM Lee; Dong-MokAACI DaeguAACO KRAAGP Lee; Dong-Mok Daegu KRAANM Lee; Eun-JuAACI DaeguAACO KRAAGP Lee; Eun-Ju Daegu KRAANM Lee; Ki-HoAACI SeoulAACO KRAAGP Lee; Ki-Ho Seoul KRAANM Cheon; Yong-PilAACI SeoulAACO KRAAGP Cheon; Yong-Pil Seoul KRAANM Chun; Tae-HoonAACI SeoulAACO KRAAGP Chun; Tae-Hoon Seoul KR - The present invention relates to a pharmaceutical composition including a testis extract serving as an active ingredient for treating and preventing anemia, in which since the testis extract induces proliferation of hematopoietic stem cell, an increase in the number of red blood cell, and an increase in the amount of hemoglobin, it is effectively used as a therapeutic agent for treating anemia related to red blood cell and hemoglobin in women of childbearing age, post-childbearing age, and during pregnancy, as well as in men. | 2013-01-17 |
20130018023 | COMPOSITIONS FOR TOPICAL ADMINISTRATION - The invention provides a composition comprising benzoyl peroxide or derivative thereof; and at least one antibiotic compound selected from pseudomonic acid, retapamulin, fusidic acid and derivatives thereof; methods and uses of a composition of the invention in the treatment of at least one topical disease or disorder and kits comprising a composition of the invention. | 2013-01-17 |
20130018024 | METHODS AND SYSTEMS FOR PHARMACOGENOMIC TREATMENT OF CARDIOVASCULAR CONDITIONS - Methods and systems are provided herein that are based on the effects of genetic variations on the biological activities associated to rostafuroxin in an individual. In particular, compositions, methods and systems are herein described that are based on an indentified influence on an individual response to rostafuroxin of one or more polymorphisms in an intergenic or intragenic region of a gene selected from the group consisting of KCNS3, THSD7A, FAM46A, LOC389970, HLA-G, and TTC29, and/or a genetic variation in linkage disequilibrium therewith. | 2013-01-17 |
20130018025 | Anticancer CompoundAANM Saifullah;AACI KarachiAACO PKAAGP Saifullah; Karachi PKAANM Khan; SaifullahAACI KarachiAACO PKAAGP Khan; Saifullah Karachi PKAANM Azizuddin;AACI KarachiAACO PKAAGP Azizuddin; Karachi PKAANM Kashif; MuhammadAACI KarachiAACO PKAAGP Kashif; Muhammad Karachi PKAANM Dar; AhsanaAACI KarachiAACO PKAAGP Dar; Ahsana Karachi PKAANM Choudhary; Muhammad IqbalAACI KarachiAACO PKAAGP Choudhary; Muhammad Iqbal Karachi PK - cell suspension culture is used to metabolize dianabol to yield potent anticarcinogenic 17β-hydroxy-17α-methyl-5α-androst-1-en-3-one, which can also be synthesized. | 2013-01-17 |
20130018026 | HALOGENATED PHENOLS FOR DIAGNOSTICS, ANTIOXIDANT PROTECTION AND DRUG DELIVERY - The present invention provides compositions and methods for the targeted delivery, release and/or formation of a drug compound at a target site(s) within the body of an individual, such as a diseased and/or inflamed tissue in the body of the individual. These compositions may comprise a halogenated phenol ring cleavably linked to a core structure of a drug compound. Due to the variety of substituents that may be utilized in forming the different types of linkages, numerous examples of drug compounds linked to a halogenated phenol ring are proposed. The present invention further provides compositions comprising halogenated phenol starting compounds that do not undergo cleavage during a dehalogenation reaction to form a drug compound in a targeted tissue when administered to an individual. Methods of administering these non-cleaving compounds are further provided. | 2013-01-17 |
20130018027 | COMPOSITIONS AND METHODS FOR NON-TOXIC DELIVERY OF ANTIPROGESTINS - The subject matter of the instant invention is pertinent to the field of treatment of hormone-dependent conditions. New compounds and methods for treating these conditions are disclosed. Embodiments of the instant invention disclose methods for treating endometriosis, dysmenorrhea, breast cancer, uterine fibroids and endometrial hyperproliferation. | 2013-01-17 |
20130018028 | Bi-(indole-2-aceto)-iron II (Ferrous Indole Acetate)AANM Farag; Christine MaherAACI LakelandAAST FLAACO USAAGP Farag; Christine Maher Lakeland FL US - Bi-(indole-2-aceto)-iron II, also named ferrous bis(indole acetate), or a pharmaceutically acceptable salt thereof, wherein: —Fe (Iron) is substituted by another transition metal capable of bonding to two molecules of indole acetate is synthesized for medicinal purposes including treatment of solid tumor cancers and other vascular proliferative disorders. This invention also extends to the substitution of the ligands by one or more of the structural analogues of indole acetetate disclosed in this application. In certain aspects, the compositions of the invention are capable of generating both a vascular targeting effect and tumor cell cytotoxicity (e.g. by oxidative stress) in order to achieve an enhanced anti-tumor response. | 2013-01-17 |
20130018029 | HIGH PENETRATION PRODRUG COMPOSITIONS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS - The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of antimicrobials and antimicrobial-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate. | 2013-01-17 |
20130018030 | New compounds, pharmaceutical compositions and uses thereofAANM HIMMELSBACH; FrankAACI MittelbiberachAACO DEAAGP HIMMELSBACH; Frank Mittelbiberach DEAANM LANGKOPF; ElkeAACI Biberach an der RissAACO DEAAGP LANGKOPF; Elke Biberach an der Riss DEAANM NOSSE; BerndAACI Biberach an der RissAACO DEAAGP NOSSE; Bernd Biberach an der Riss DE - The present invention relates to compounds of general formula I, | 2013-01-17 |
20130018031 | AMINOALKYLPYRIMIDINE DERIVATIVES AS HISTAMINE H4 RECEPTOR ANTAGONISTS - Aminoalkylpyrimidine derivatives of formula I, wherein the meaning of the different substituents are those indicated in the description. These compounds are useful as histamine H | 2013-01-17 |
20130018032 | INHIBITORS OF BRUTON'S TYROSINE KINASE - Described herein are kinase inhibitor compounds, methods for synthesizing such inhibitors, and methods for using such inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate inhibitor of a protein, including a kinase. | 2013-01-17 |
20130018033 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF - Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. | 2013-01-17 |
20130018034 | AZETIDINYL PHENYL, PYRIDYL OR PYRAZINYL CARBOXAMIDE DERIVATIVES AS JAK INHIBITORS - The present invention provides azetidinyl phenyl, pyridyl, or pyrazinyl carboxamide derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase (JAKs) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases. | 2013-01-17 |
20130018035 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE - The present invention relates to pyrrolopyrazines compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. | 2013-01-17 |
20130018036 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS - Substituted indazole derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful in therapy in the treatment of diseases associated with a deregulated protein kinase activity, like cancer. | 2013-01-17 |
20130018037 | Compounds - 801 - Spirocyclic amide derivatives of formula I | 2013-01-17 |
20130018038 | CHEMICAL COMPOUNDS - The invention is directed to substituted indoline derivatives. Specifically, the invention is directed to compounds according to Formula I: | 2013-01-17 |
20130018039 | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS - Disclosed are compounds having the formula: wherein R | 2013-01-17 |
20130018040 | Compositions And Methods For Treating Toxoplasmosis, Cryptosporidiosis, And Other Apicomplexan Protozoan Related Diseases - Compositions and methods for the treatment of toxoplasmosis, caused by the infectious eukaryotic parasite | 2013-01-17 |
20130018041 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES - This invention is directed to compounds of formula (I): | 2013-01-17 |
20130018042 | Toll-Like Receptor Agonist Formulations and Their Use - The present invention is directed generally to stable formulations of a TLR agonist preferably a TLR7 or a TLR8 agonist, for use in the treatment of cancer, preferably solid tumors and lymphomas. Specifically, the present invention is directed to stable formulations of up to 50 mg/ml of a TLR agonist which comprise a cyclodextrin. | 2013-01-17 |
20130018043 | AMINOMETHYL QUINOLONE COMPOUNDS - The invention relates to JNK inhibitors and corresponding methods, formulations, and compositions for inhibiting JNK and treating JNK-mediated disorders. The application discloses JNK inhibitors, as described below in Formula I: | 2013-01-17 |
20130018044 | NEW INHIBITORS OF CYCLOPHILINS AND USES THEREOFAANM Guichou; Jean-FrancoisAACI MontpellierAACO FRAAGP Guichou; Jean-Francois Montpellier FRAANM Colliandre; LionelAACI Orleans Cedex 2AACO FRAAGP Colliandre; Lionel Orleans Cedex 2 FRAANM Ahmed-Belkacem; HakimAACI CreteilAACO FRAAGP Ahmed-Belkacem; Hakim Creteil FRAANM Pawlotsky; Jean-MichelAACI CreteilAACO FRAAGP Pawlotsky; Jean-Michel Creteil FR - The present invention relates to a compound of formula (I): | 2013-01-17 |
20130018045 | New Chemical Entities To Be Used For Wee1 Inhibition For The Treatment Of Cancer - The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, | 2013-01-17 |
20130018046 | Acetylenic Heteroaryl Compounds - This invention relates to compounds of the general formula: | 2013-01-17 |
20130018047 | N-PHENYL-(PIPERAZINYL OR HOMOPIPERAZINYL)-BENZENESULFONAMIDE OR BENZENESULFONYL-PHENYL-(PIPERAZINE OR HOMOPIPERAZINE) COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR - The present invention relates to N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds, pharmaceutical compositions containing them, and their use in therapy. The compounds possess valuable therapeutic properties and are particularly suitable for treating diseases that respond to modulation of the serotonin 5-HT | 2013-01-17 |
20130018048 | OXAZOLE DERIVATIVES USEFUL AS MODULATORS OF FAAH - The present invention is directed to certain Oxazole derivatives which are useful as modulators of Fatty Acid Amide Hydrolase (FAAH) and as FAAH imaging agents. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzheimer Disease, and Parkinson's Disease. | 2013-01-17 |
20130018049 | Azaindole Compounds and Methods for Treating HIV - Provided are compounds and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and their use for treating viral infections mediated by a member of the retrovirus family of viruses such as the Human Immunodeficiency Virus (HIV). | 2013-01-17 |
20130018050 | BI-FUNCTIONAL PYRAZOLOPYRIDINE COMPOUNDS - This invention provides compounds of the formula: | 2013-01-17 |
20130018051 | BRIDGED BICYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS - Bridged bicyclic heteroaryl substituted triazoles and pharmaceutical compositions containing the compounds are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the compounds in treating diseases or conditions associated with Axl activity are also disclosed. | 2013-01-17 |
20130018052 | 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS ALK5 AND/OR ALK4 INHIBITORS - The present invention provides a novel 2-pyridyl substituted imidazole derivative, or a pharmaceutically acceptable salt or solvate thereof, which selectively inhibits the transforming growth factor-β (TGF-β) type I receptor (ALK5) and/or the activin type I receptor (ALK4); a pharmaceutical composition comprising same as an active ingredient; and a use of the 2-pyridyl substituted imidazole derivative for the manufacture of a medicament for preventing or treating a disease mediated by ALK5 and/or ALK4 receptors in a mammal. | 2013-01-17 |
20130018053 | SUBSTITUTED PYRIMIDINES - The present invention relates to substituted pyrimidines useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions. | 2013-01-17 |
20130018054 | NEW COMPOUNDS - The present invention provides organic compounds of the following structure; A-L1-B—C-D-L2-E that are useful for treating or preventing conditions or disorders associated with DGAT1 activity in animals, particularly humans. | 2013-01-17 |
20130018055 | NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVESAANM Aebi; JohannesAACI BinningenAACO CHAAGP Aebi; Johannes Binningen CHAANM Binggeli; AlfredAACI BinningenAACO CHAAGP Binggeli; Alfred Binningen CHAANM Hertel; CorneliaAACI BrislachAACO CHAAGP Hertel; Cornelia Brislach CHAANM Konkar; Anish AshokAACI BinningenAACO CHAAGP Konkar; Anish Ashok Binningen CHAANM Kuehne; HolgerAACI LoerrachAACO DEAAGP Kuehne; Holger Loerrach DEAANM Kuhn; BerndAACI Reinach BLAACO CHAAGP Kuhn; Bernd Reinach BL CHAANM Maerki; Hans P.AACI BaselAACO CHAAGP Maerki; Hans P. Basel CHAANM Wang; HaiyanAACI AllschwilAACO CHAAGP Wang; Haiyan Allschwil CH - The invention provides novel compounds having the general formula (I) | 2013-01-17 |
20130018056 | METHOD OF TREATMENT FOR MENTAL DISORDERS - The invention relates to a medicament or a method for treating mental disorders, in detail, ADHD comprising lurasidone, or a combination of lurasidone and a D | 2013-01-17 |
20130018057 | Quinoline and Quinoxaline Derivatives as Kinase InhibitorsAANM Burli; RolandAACI Saffron Walden EssexAACO GBAAGP Burli; Roland Saffron Walden Essex GBAANM Haughan; Alan FindlayAACI Saffron Walden EssexAACO GBAAGP Haughan; Alan Findlay Saffron Walden Essex GBAANM Matteucci; M zioAACI Saffron Walden EssexAACO GBAAGP Matteucci; M zio Saffron Walden Essex GBAANM Owens; Andrew PateAACI Saffron Walden EssexAACO GBAAGP Owens; Andrew Pate Saffron Walden Essex GBAANM Raphy; GillesAACI Saffron Walden EssexAACO GBAAGP Raphy; Gilles Saffron Walden Essex GBAANM Sharpe; AndrewAACI Saffron Walden EssexAACO GBAAGP Sharpe; Andrew Saffron Walden Essex GB - A series of quinoline and quinoxaline derivatives, substituted by a fused bicyclic pyridine or pyrimidine moiety attached via an alkylene chain optionally linked to a heteroatom, being selective inhibitors of P13 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions. | 2013-01-17 |
20130018058 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES - A lacate salt of a compound of Formula I or a tautomer of the compound, wherein Formula I has the following structure and R | 2013-01-17 |
20130018059 | DIMETHYL SULFOXIDE (DMSO) FORMULATIONS FOR TREATING AUTISM - Embodiments of the invention relate generally to formulations comprising dimethyl sulfoxide (DMSO) to treat behavioral disorders, communication delays, and developmental delays. Several formulations disclosed herein are useful for treating broad autism phenotype disorders, including autism spectrum disorders (e.g., autism). | 2013-01-17 |
20130018060 | INHIBITORS OF BRUTON'S TYROSINE KINASE - Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase. | 2013-01-17 |
20130018061 | Method for Improving Exercise and Recovery From ExerciseAANM Bashir; RazaAACI OakvilleAACO CAAAGP Bashir; Raza Oakville CAAANM Wissent; CraigAACI OakvilleAACO CAAAGP Wissent; Craig Oakville CA - A method for improving exercise performance and recovery from exercise is provided. The method involves administration of a specific ratio of caffeine and L-theanine. The method is useful for any individual participating in exercise and may be particularly beneficial for individuals accustomed to regular, high caffeine intake. | 2013-01-17 |
20130018062 | Pain therapy with metabolism blocked antifolatesAANM Nair; Madhavan G.AACI MobileAAST ALAACO USAAGP Nair; Madhavan G. Mobile AL US - The perception of pain precedes the manifestation of measurable and quantifiable clinical symptoms of most diseases. Pain is an early warning signal at the beginning of a physical abnormality. The present invention discloses novel methods to ameliorate or reverse diseases at their warning stages by therapeutic intervention of pain before a definite clinical diagnosis of the abnormality can be made. Unprecedented methods to eliminate pain caused by inflammatory autoimmune response or inflammatory allergic response or malignant and benign neoplastic growth by administering metabolism blocked antifolate compounds are described. | 2013-01-17 |
20130018063 | ORGANIC COMPOUNDS - The invention provides novel 7,8-dihydro-imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4-one compounds and 7,8,9-trihydro-[1H or 2H]-pyrimido[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one compounds, substituted at the 1 or 2 position with C | 2013-01-17 |
20130018064 | Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of UseAANM Paras; Nick A.AACI San FranciscoAAST CAAACO USAAGP Paras; Nick A. San Francisco CA USAANM Cheng; YuanAACI Newbury ParkAAST CAAACO USAAGP Cheng; Yuan Newbury Park CA USAANM Powers; TimothyAACI MalibuAAST CAAACO USAAGP Powers; Timothy Malibu CA USAANM Brown; JamesAACI MoorparkAAST CAAACO USAAGP Brown; James Moorpark CA USAANM Hitchcock; Stephen A.AACI JupiterAAST FLAACO USAAGP Hitchcock; Stephen A. Jupiter FL USAANM Judd; TedAACI Simi ValleyAAST CAAACO USAAGP Judd; Ted Simi Valley CA USAANM Lopez; PatriciaAACI West HillsAAST CAAACO USAAGP Lopez; Patricia West Hills CA USAANM Xue; QiufenAACI Newbury ParkAAST CAAACO USAAGP Xue; Qiufen Newbury Park CA USAANM Yang; BryantAACI Simi ValleyAAST CAAACO USAAGP Yang; Bryant Simi Valley CA US - The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I, wherein ring A, B | 2013-01-17 |
20130018065 | PROCESSES FOR THE PREPARATION OF KEY INTERMEDIATE FOR THE SYNTHESIS OF ROSUVASTATIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOFAANM Andrensek; SamoAACI LjubljanaAACO SIAAGP Andrensek; Samo Ljubljana SIAANM Anzel; JolandaAACI LjubljanaAACO SIAAGP Anzel; Jolanda Ljubljana SIAANM Hocevar; MarjetaAACI LjubljanaAACO SIAAGP Hocevar; Marjeta Ljubljana SIAANM Casar; ZdenkoAACI LjubljanaAACO SIAAGP Casar; Zdenko Ljubljana SI - The present invention relates in general to the field of organic chemistry and in particular to a process for the preparation of 5-((E)-2-((2S,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl)vinyl)-4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-methanesulfonylamino)pyrimidine (RSVL) as well as a process for preparing crystalline 5-((E)-2-((2S,4R)-4-(tert-butyldimethylsilyloxy)-6-oxotetrahydro-2H-pyran-2-yl)vinyl)-4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethanesulfonylamino)pyrimidine (RSVLTBS) useful as key intermediates for the preparation of rosuvastatin or pharmaceutically acceptable salts thereof. | 2013-01-17 |
20130018066 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS - Disclosed are compounds of the formula I | 2013-01-17 |
20130018067 | POLYCYCLIC PYRROLIDINE-2,5-DIONE DERIVATIVES AS -FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS - The present invention relates to novel polycyclic pyrrolidine-2,5-dione derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor. | 2013-01-17 |
20130018068 | SPIROCYCLES AS INHIBITORS OF 11-BETA HYDROXYL STEROID DEHYDROGENASE TYPE 1 - The present invention relates to certain spirocyclic compounds that are inhibitors of 11-β hydroxyl steroid dehydrogenase type 1 (11βHSD1), compositions containing the same, and methods of using the same for the treatment of diabetes, obesity and other diseases. | 2013-01-17 |
20130018069 | SUSTAINED RELEASE DELIVERY SYSTEMS FOR THE PREVENTION AND TREATMENT OF HEAD AND NECK CANCERS - The present invention discloses a method of treating a head and neck cancer or preventing the development of pre-malignant lesions to this cancer, by administering locally to the oral cavity, a sustained release drug delivery system comprising a drug for the treatment of this cancer or for the prevention of said lesions, and at least one polymer, such that said system is attached to a surface in the oral cavity and remains attached thereto for at least 1 hour, accompanied by release of the drug and maintaining an effective therapeutic concentration thereof in the cavity, for at least 1 hour. Further are disclosed a sustained release drug delivery system and a liquid precursor varnish composition to this system. | 2013-01-17 |
20130018070 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR - The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators. | 2013-01-17 |
20130018071 | Solid Forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline- -3-carboxamide - The present invention relates to solid state forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith. | 2013-01-17 |
20130018072 | AMINOPYRAZOLE TRIAZOLOTHIADIAZOLE INHIBITORS OF C-MET PROTEIN KINASE - The present invention relates to compounds of formula I, which is useful in the inhibition of c-Met protein kinase. The invention also provides pharmaceutically acceptable compositions comprising compounds of formula I and methods of using the compositions in the treatment of proliferative disorders. | 2013-01-17 |
20130018073 | INDOLE DERIVATIVEAANM Masada; ShinichiAACI KanagawaAACO JPAAGP Masada; Shinichi Kanagawa JPAANM Terao; YoshitoAACI KanagawaAACO JPAAGP Terao; Yoshito Kanagawa JPAANM Murata; ToshikiAACI KanagawaAACO JPAAGP Murata; Toshiki Kanagawa JP - The present invention provides an indole derivative having a melanin-concentrating hormone receptor antagonistic action, which is useful as an agent for the prophylaxis or treatment of obesity and the like. | 2013-01-17 |
20130018074 | NEW COMPOUNDS - The present invention provides organic compounds of the following structure; A-L1-B—C-D-L2-E that are useful for treating or preventing conditions or disorders associated with DGAT1 activity in animals, particularly humans. | 2013-01-17 |
20130018075 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF - Disclosed are methods of treating hyperproliferative disorders, method of treating inflammatory disorders, and methods of inhibiting MEK activity in a mammal, comprising administering an effective amount of one or more compounds of the Formula V | 2013-01-17 |
20130018076 | TRIGONELLINE AS A MUSCLE STIMULANT - This invention relates to the use of trigonelline compounds to increase muscle weight during periods of activity or to inhibit muscle loss during periods of inactivity. | 2013-01-17 |
20130018077 | ALKYNYL PHENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS - Provided are alkynyl phenyl derivative compounds, pharmaceutical compositions thereof, and methods of treating ophthalmic diseases and disorders, such as age-related macular degeneration and Stargardt's Disease, using said compounds and compositions. | 2013-01-17 |
20130018078 | ADHESIVE MIXTURE FOR TRANSDERMAL DELIVERY OF HIGHLY PLASTICIZING DRUGS - Transdermal drug delivery patches and methods of their production are described. The patches can be made such that the accommodate highly plasticizing drugs such as selegiline and/or the use of protonated forms of various drugs. | 2013-01-17 |
20130018079 | ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE THEREOF - Described herein is a novel class of inhibitors of bacterial cell division. Several lines of evidence suggest the compounds disclosed herein specifically target the division process and have antibacterial activity in vitro and in vivo. The inhibitors are useful for treating subject in need of treatment for bacterial infections as will as for inhibiting bacterial growth, such as growth on contaminated surfaces. | 2013-01-17 |
20130018080 | COMPOSITIONS COMPRISING AMINO ACIDS FOR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASEAANM Dioguardi; Francesco SaverioAACI MilanoAACO ITAAGP Dioguardi; Francesco Saverio Milano ITAANM Mella; Isabella ArborioAACI MilanoAACO ITAAGP Mella; Isabella Arborio Milano ITAANM Conti; Edoardo Carlo MariaAACI MilanoAACO ITAAGP Conti; Edoardo Carlo Maria Milano ITAANM Conti; Giovanni Federico MariaAACI MilanoAACO ITAAGP Conti; Giovanni Federico Maria Milano IT - A composition comprising leucine, isoleucine, valine, threonine and lysine for treating chronic obstructive pulmonary disease. | 2013-01-17 |
20130018081 | AChE ANTISENSE OLIGONUCLEOTIDE AS AN ANTI-INFLAMMATORY AGENT - Disclosed is a novel use for AChE antisense oligonucleotides as anti-inflammatory agents, wherein said oligonucleotides are preferably as denoted by SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:7. Methods of treatment of inflammatory conditions, as well as fever, and particularly inflammation-associated neuropathies such as Guillain-Barré Syndrome, are described. | 2013-01-17 |
20130018082 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) - The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism. | 2013-01-17 |
20130018083 | USE OF SIRNA TARGETTING SIPA1L1 FOR THE REDUCTION OF ADIPOGENESISAANM Hall; DianaAACI LausanneAACO CHAAGP Hall; Diana Lausanne CHAANM Jimenez; MariaAACI Chavannes-pres-RenensAACO CHAAGP Jimenez; Maria Chavannes-pres-Renens CHAANM Poussin; CarineAACI Evian-les-BainsAACO FRAAGP Poussin; Carine Evian-les-Bains FRAANM Thorens; BernardAACI EpalingesAACO CHAAGP Thorens; Bernard Epalinges CH - The present invention concerns Sipa1l1, a new target involved in adipogenesis modulation. Using a siRNA approach, the inventors demonstrated that decrease in Sipa1l1 activity in preadipocytes and adipose tissue induces a decrease in adipogenesis. Thus, the present invention relates to modulators of Sipa1l1 activity as well as screening test for identification of modulators of the activity of this target, and their use, especially in pharmaceutical composition, to modulate adipogenesis and thus treat obesity and related disorders. | 2013-01-17 |
20130018084 | MICRORNA (miRNA) AND DOWNSTREAM TARGETS FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES - In some embodiments, the present invention concerns antisense oligonucleotides against targets of miR-21. In some embodiments, the invention is directed to a method for diagnosing fibrosis and/or fibrosis related diseases and to a method for screening a pharmaceutically active compound for the treatment of fibrosis and/or fibrosis related diseases. The present invention further relates to compositions for use in the treatment, amelioration, and/or prevention of fibrosis. In certain embodiments, the compositions modulate the activity of a miRNA for the treatment, amelioration, and/or prevention of fibrosis. In certain embodiments, the compositions inhibit the activity of miR-21 for the treatment, amelioration, and/or prevention of fibrosis. | 2013-01-17 |
20130018085 | iRNA Agents Targeting VEGF - The features of the present invention relate to compounds, compositions and methods useful for modulating the expression of vascular endothelial growth factor (VEGF), such as by the mechanism of RNA interference (RNAi). The compounds and compositions include iRNA agents that can be unmodified or chemically-modified. | 2013-01-17 |
20130018086 | SIRNAS TARGETING EXON 10 OF PYRUVATE KINASE M2 - The invention relates to nucleic acid molecules and compositions for specific post-transcriptional inhibition of PKM2 expression. Methods for specific inhibition of PKM2 expression in a target cell, for example a cancer cell, are also provided. | 2013-01-17 |
20130018087 | miRNA Compounds for Treatment of Prostate CarcinomaAANM Boll; KerstinAACI LeipzigAACO DEAAGP Boll; Kerstin Leipzig DEAANM Horn; FriedemannAACI LeipzigAACO DEAAGP Horn; Friedemann Leipzig DEAANM Hackermuller; JorgAACI LeipzigAACO DEAAGP Hackermuller; Jorg Leipzig DE - The invention inter alia relates to new pharmaceutical compositions comprising miRNAs mi R-130a, mi R-203 and miR-205, and their use for the treatment of cancer, in particular prostate cancer. F 8812/DB | 2013-01-17 |
20130018088 | METHODS AND COMPOSITIONS FOR ANTI-EGFR TREATMENT - In some embodiments, the present invention provides methods for enhancing the sensitivity of cancer cells to anti-EGFR treatment, wherein the method comprises the introduction of a miR-200 miRNA to the cancer cells. In other embodiments, the present invention provides methods for treating cancer by exposing the cancer cells to an anti-EGFR composition after the above-mentioned enhancement step. In other embodiments, the present invention provides methods for assessing and enhancing the sensitivity of cancer cells to anti-EGFR treatment. In various other embodiments, the present invention provides compositions and expression vectors for practicing the afore-mentioned methods. | 2013-01-17 |
20130018089 | METHOD OF TREATING INFLAMMATORY ARTHROPATHIES WITH SUPPRESSORS OF CPG OLIGONUCLEOTIDES - The present disclosure relates to oligodeoxynucleotides that suppress an immune response. Methods are disclosed for preventing or treating inflammatory arthropathies by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide. | 2013-01-17 |
20130018090 | LOW-DOSE DOXEPIN FOR TREATMENT OF SLEEP DISORDERS IN ELDERLY PATIENTS - Methods of treating sleep disorders, particularly certain aspects of insomnia, in elderly patients (65 years and older) by administering initial daily dosages of doxepin of 1-3 mg. These ultra-low initial dosages are more effective in elderly versus non-elderly patients in decreasing wake time during sleep, latency to persistent sleep and wake time after sleep, and are particularly efficacious in treating those conditions in the last hour of an 8-hour sleep cycle. Also, the dosages described herein are safe for elderly individuals. | 2013-01-17 |
20130018091 | TREATMENT OF ALLODYNIA AND HYPERALGESIA - The present invention relates to the treatment or prevention of allodynia and/or hyperalgesia, and to tonabersator an analogueof formula (1), and compositions comprising tonabersat or an analogue of formula (1) for use in said treatments. | 2013-01-17 |
20130018092 | TREATMENT FOR HYPOXIA - The invention provides a method for treating hypoxia in a normal subject, comprising administering 5-HMF to the subject. | 2013-01-17 |
20130018093 | NOVEL EPOPROSTENOL FORMULATION AND METHOD OF MAKING THEREOF - This invention relates to a stable epoprostenol composition that can be combined with commercially available IV fluids and can be administered in its reconstituted and/or diluted form under ambient conditions of about 15-30° C. for greater than 24 hours. The composition preferably contains (a) epoprostenol or a salt thereof; (b) a alkalinization agent; and (c) a base, such that when reconstituted or in solution, the solution has a pH>11. Methods for making the lyophilized composition are also disclosed. | 2013-01-17 |
20130018094 | Prophylactic or Therapeutic Agent For Gum Disease or Apical PeriodontitisAANM Kawashima; NobuyukiAACI TokyoAACO JPAAGP Kawashima; Nobuyuki Tokyo JPAANM Suzuki; NoriyukiAACI TokyoAACO JPAAGP Suzuki; Noriyuki Tokyo JP - Monosodium (2S,3S)-3-[[(1S)-1-isobutozymethyl-3-methylbutyl]-carbamoyl]oxirane-2-carboxylate represented by the following formula is used as a prophylactic or therapeutic agent for periodontal diseases including gum disease and apical periodontitis. | 2013-01-17 |
20130018095 | Fumigillol Type Compounds and Methods of Making and Using Same - The disclosure provides a fumagillol type compound and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of using, e.g. in the treatment of obesity are provided. | 2013-01-17 |
20130018096 | PLATINUM COMPLEX WITH ANTITUMOR ACTIVITYAANM De Munari; SergioAACI MilanAACO ITAAGP De Munari; Sergio Milan ITAANM Di Giovine; StefanoAACI MilanAACO ITAAGP Di Giovine; Stefano Milan ITAANM Grugni; MarioAACI MilanAACO ITAAGP Grugni; Mario Milan ITAANM Nicoli; PaolaAACI MilanAACO ITAAGP Nicoli; Paola Milan ITAANM Paganelli; AlessandroAACI MilanAACO ITAAGP Paganelli; Alessandro Milan ITAANM Pardi; GianlucaAACI San Giuliano Terme (Pisa)AACO ITAAGP Pardi; Gianluca San Giuliano Terme (Pisa) ITAANM Pezzoni; GabriellaAACI MilanAACO ITAAGP Pezzoni; Gabriella Milan IT - The present invention relates to the antitumor compound of formula (I) a process for its preparation and pharmaceutical compositions containing it. | 2013-01-17 |
20130018097 | ENHANCED MICROBIAL PERACID COMPOSITIONS AND METHODS OF USE AT REDUCED TEMPERATURES IN ASEPTIC CLEANING - The present invention relates to compositions of peracids, such as peroxycarboxylic acids, having improved antimicrobial efficacy due to ethanol solubilization of the compositions. The enhanced antimicrobial efficacy of the peracid compositions beneficially have a lower use concentration. The invention further relates to methods employing such compositions. | 2013-01-17 |
20130018098 | PYRETHRINOID-TYPE ESTERS AS PESTICIDESAANM Matsuo; NoritadaAACI Amagasaki-shiAACO JPAAGP Matsuo; Noritada Amagasaki-shi JPAANM Mori; TatsuyaAACI Toyonaka-shiAACO JPAAGP Mori; Tatsuya Toyonaka-shi JP - An ester compound represented by formula (1): wherein R | 2013-01-17 |
20130018099 | DEODORIZATION OF PERACIDS - The present invention relates to compositions of peracids, such as peroxycarboxylic acids, having reduced odor compared to conventional peracid compositions. The invention further relates to methods employing such compositions, and methods of making these compositions. Typically, the reduced-odor antimicrobial compositions include an alcohol for the esterification reaction to remove short- to mid-chain length malodorous carboxylic acids. | 2013-01-17 |
20130018100 | Tranexamic Acid Formulations - Disclosed are modified release oral tranexamic acid formulations and methods of treatment therewith. | 2013-01-17 |
20130018101 | SALTS OF FENOFIBRIC ACID AND PHARMACEUTICAL FORMULATIONS THEREOF - In one aspect, the present invention relates to a formulation in the form of molecular dispersion comprising i) fenofibric acid, a physiologically acceptable salt or derivative thereof and optionally other active substances, ii) a binder component comprising at least one enteric binder, and optionally iii) other physiologically acceptable excipients. | 2013-01-17 |
20130018102 | NUTRITIONAL SUPPLEMENT FOR THE ENHANCEMENT OF MUSCLE PERFORMANCE AND RECOVERY - Described herein are nutritional supplements containing α-hydroxy-isocaproic acid and aspartic acid (e.g., DAA) and their methods of use in enhancing muscle performance and/or recovery after exercise. The nutritional supplements can be used to enhance muscle building and lean body mass, enhance muscle and physical performance, enhance recovery, and prevent catabolism (muscle atrophy or wasting) when administered to a mammalian subject. | 2013-01-17 |
20130018103 | BIFUNCTIONAL HISTONE DEACETYLASE INHIBITORS - In recognition of the need to develop novel therapeutic agents and efficient methods for the synthesis thereof, the present invention provides novel bifunctional, trifunctional, or multifunctional compounds for inhibiting histone deacetylases, and pharmaceutically acceptable salts and derivatives thereof. The present invention further provides methods for treating disorders regulated by histone deacetylase activity (e.g., proliferative diseases, cancer, inflammatory diseases, protozoal infections, hair loss, etc.) comprising administering a therapeutically effective amount of an inventive compound to a subject in need thereof. The present invention also provides methods for preparing compounds of the invention. | 2013-01-17 |
20130018104 | EMULSIVE COMPOSITION CONTAINING DAPSONE - The present invention relates to a topical, emulsive composition containing Dapsone or its derivative. The inventive composition incorporates emollients and Dapsone or its derivative in a stable emulsion. The stability is achieved through the use of a combination of certain surfactant mixtures and an enhancer providing solubility of the Dapsone. | 2013-01-17 |
20130018105 | CIS, 3,4-DIHYDROXY-2-(3-METHYLBUTANOYL)-5-(3-METHYLBUTYL)-4-(4-METHYLPENTA- NOYL)CYCLOPENT-2-EN-1-ONE DERIVATIVES, SUBSTANTIALLY ENANTIOMERICALLY PURE COMPOSITIONS AND METHODS - The present application provides cis 3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one derivatives and substantially enantiomerically pure compositions thereof. These derivatives include (+)-(4S,5R)—3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one, (−)-(4R,5S)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one, and salts and crystals thereof. The application further provides methods of using the disclosed compounds and compositions to activate PPARγ, activate GPR120, inhibit inflammation, and treat conditions responsive to PPARγ modulation, conditions responsive to GPR120 modulation, and metabolic disturbances such as diabetes. | 2013-01-17 |
20130018106 | HOP ACIDS AS A REPLACEMENT FOR ANTIBIOTICS IN ANIMAL FEED - A method of using hop acids for increasing food and energy uptake from feed by livestock is described which includes delivering the hop acids for oral ingestion to the animals by mixing the acids with livestock feed. The acids are mixed with the feed in an amount to inhibit certain types of undesirable bacteria in the livestock's digestive system, thereby increasing the production of propionate and lactate and decreasing the production of methane gas. | 2013-01-17 |
20130018107 | Cinnamaldehyde and Diallyl Disulfide Formulations and Methods of Use - The present invention relates to agricultural emulsion concentrates which form stable oil-in-water emulsions when diluted with water. More specifically, the invention relates to stable oil-in-water emulsions which include cinnamaldehyde and diallyl disulfide with a Calsogen® EH and Surfonic® CO 36 emulsion system. The increased stability of the emulsion allows for efficient mixing of the emulsion ingredients and effective storage and application of the cinnamaldehyde and diallyl disulfide to areas in need of nematode protection or treatment. | 2013-01-17 |
20130018108 | METHOD OF PRODUCING HIGH ALCOHOL CONTENT FOAMING COMPOSITIONS WITH SILICONE-BASED SURFACTANTS - This invention relates to a method of producing and dispensing a foam using a “high lower alcohol content” (>40% v/v of a C | 2013-01-17 |
20130018109 | Skin and hair treatments - Linalool and other materials which are skin penetrating vasodilators or which can be made to have such properties are applied, either by themselves or in skin treatment compositions, to the skin of the head and especially the back of the neck to prevent or alleviate the effects of migraine headaches or applied to sore muscles or ligaments to aid in minimizing the soreness, or are applied to wrinkled and/or old looking skin on the face, neck, torso, or extremities, other than on the hands, to minimize wrinkles and/or improve the skin's appearance and/or are applied to the head to grow hair on the head or prevent hair loss. | 2013-01-17 |
20130018110 | HYDROGEL SYNTHESISAANM Khutoryanskiy; VitaliyAACI ReadingAACO GBAAGP Khutoryanskiy; Vitaliy Reading GBAANM Khutoryanskaya; OlgaAACI ReadingAACO GBAAGP Khutoryanskaya; Olga Reading GBAANM Cook; Joseph PeterAACI ReadingAACO GBAAGP Cook; Joseph Peter Reading GBAANM Goodall; Glenn WilliamAACI PeterboroughAACO GBAAGP Goodall; Glenn William Peterborough GB - The invention provides a method for preparing a hydrogel from a hydrophilic polymer having one or more functional groups which are capable of co-reacting in a condensation reaction which method comprises the steps of: (i) preparing a solution of the polymer; (ii) heating the solution to a temperature sufficient for the condensation reaction to take place for a period of time sufficient for the hydrogel to cross-link wherein where the hydrophilic polymer comprises a first and a second hydrophilic polymer, step (i) comprises a step of mixing the hydrophilic polymers to prepare a homogeneous intimate mixture of the polymers; and wherein the heating step (ii) is carried out at a pressure greater than atmospheric pressure. The method of the invention is advantageous because it is relatively low cost, it is a safer procedure with less health & safety concerns, it is carried out in a liquid state and is not limited by film thickness. | 2013-01-17 |
20130018111 | BIODEGRADABLE AND BIOCOMPATIBLE SHAPE MEMORY POLYMERS - This invention relates to shape memory block copolymers comprising: at least one switching segment having a T | 2013-01-17 |
20130018112 | CELLULOSE NANOPARTICLE AEROGELS, HYDROGELS AND ORGANOGELSAANM Thielemans; Wim Albert Wilfried IreneAACI NottinghamAACO GBAAGP Thielemans; Wim Albert Wilfried Irene Nottingham GBAANM Davies; RebeccaAACI NottinghamAACO GBAAGP Davies; Rebecca Nottingham GB - A cellulose aerogel comprises a plurality of cellulose nanoparticles. The cellulose nanoparticles preferably comprise at least 50% or 80% cellulose nanocrystals by weight of cellulose nanoparticles, and the cellulose nanoparticle aerogel preferably has a density of from 0.001 to 0.2 g/cm | 2013-01-17 |